Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABC
ABcann Global
C$0.00
C$0.00
C$0.00
N/AN/AN/AN/A
BTG
B2Gold
$2.80
-1.8%
$0.00
$2.34
$3.92
$3.66B1.111.49 million shs10.04 million shs
Cronos Group Inc. stock logo
CRON
Cronos Group
$2.59
+3.6%
$2.65
$1.64
$3.14
$989.41M1.112.97 million shs1.44 million shs
Genius Group Limited stock logo
GNS
Genius Group
$0.31
-1.8%
$0.00
$0.24
$2.48
$22.75M11.975.34 million shs1.58 million shs
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$18.44
$18.12
$5.80
$20.96
$1.94B2.081.87 million shs8 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BTG
B2Gold
0.00%+1.45%+279,999,900.00%+279,999,900.00%+279,999,900.00%
Cronos Group Inc. stock logo
CRON
Cronos Group
0.00%-1.89%-3.36%+34.20%+48.00%
Genius Group Limited stock logo
GNS
Genius Group
0.00%0.00%0.00%0.00%-69.33%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ABC
ABcann Global
N/AN/AN/AN/AN/AN/AN/AN/A
BTG
B2Gold
N/AN/AN/AN/AN/AN/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
0.3564 of 5 stars
1.53.00.00.02.50.00.6
Genius Group Limited stock logo
GNS
Genius Group
N/AN/AN/AN/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ABC
ABcann Global
N/AN/AN/AN/A
BTG
B2Gold
N/AN/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
1.00
Sell$3.0015.83% Upside
Genius Group Limited stock logo
GNS
Genius Group
N/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest ABC, BTG, GNS, CRON, and TRIL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2024
Cronos Group Inc. stock logo
CRON
Cronos Group
CIBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperformer ➝ Outperformer$3.00 ➝ $3.50
4/8/2024
Cronos Group Inc. stock logo
CRON
Cronos Group
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$2.00 ➝ $2.50
(Data available from 6/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ABC
ABcann Global
N/AN/AN/AN/AN/AN/A
BTG
B2Gold
$1.93B1.89$0.57 per share4.87$3.01 per share0.93
Cronos Group Inc. stock logo
CRON
Cronos Group
$87.24M11.34N/AN/A$2.81 per share0.92
Genius Group Limited stock logo
GNS
Genius Group
$23.06M0.99N/AN/A$0.27 per share1.14
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$150K12,907.39N/AN/A$2.56 per share7.20

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ABC
ABcann Global
N/AN/A0.00N/AN/AN/AN/AN/AN/A
BTG
B2Gold
$10.10M-$0.03N/A6.220.46-2.10%8.05%6.47%N/A
Cronos Group Inc. stock logo
CRON
Cronos Group
-$73.96M-$0.15N/A43.17N/A-61.31%-3.06%-2.97%8/13/2024 (Estimated)
Genius Group Limited stock logo
GNS
Genius Group
-$5.66MN/A0.00N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/A

Latest ABC, BTG, GNS, CRON, and TRIL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q1 2024
Cronos Group Inc. stock logo
CRON
Cronos Group
-$0.01-$0.01N/A-$0.01$24.30 million$25.29 million      
5/7/2024Q1 2024
BTG
B2Gold
$0.05$0.06+$0.01$0.09N/A$461.44 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ABC
ABcann Global
N/AN/AN/AN/AN/A
BTG
B2Gold
$0.165.71%+13.30%N/A N/A
Cronos Group Inc. stock logo
CRON
Cronos Group
N/AN/AN/AN/AN/A
Genius Group Limited stock logo
GNS
Genius Group
N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/A

Latest ABC, BTG, GNS, CRON, and TRIL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/7/2024
BTG
B2Gold
Quarterly$0.045.67%6/11/20246/11/20246/24/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ABC
ABcann Global
N/AN/AN/A
BTG
B2Gold
0.01
2.99
1.97
Cronos Group Inc. stock logo
CRON
Cronos Group
N/A
28.19
27.28
Genius Group Limited stock logo
GNS
Genius Group
0.01
0.56
0.51
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/A
19.82
19.82

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ABC
ABcann Global
N/A
BTG
B2Gold
61.40%
Cronos Group Inc. stock logo
CRON
Cronos Group
8.71%
Genius Group Limited stock logo
GNS
Genius Group
14.28%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
87.15%

Insider Ownership

CompanyInsider Ownership
ABC
ABcann Global
N/A
BTG
B2Gold
1.18%
Cronos Group Inc. stock logo
CRON
Cronos Group
6.90%
Genius Group Limited stock logo
GNS
Genius Group
51.19%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
9.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ABC
ABcann Global
N/AN/AN/ANot Optionable
BTG
B2Gold
6,1501.31 billion1.29 billionN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
356382.01 million355.65 millionOptionable
Genius Group Limited stock logo
GNS
Genius Group
47573.87 million36.06 millionNot Optionable
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
33105.00 million95.44 millionOptionable

ABC, BTG, GNS, CRON, and TRIL Headlines

Recent News About These Companies

Cachet Bicycle shakes off COVID
BridgeBio raises $1.25bn, and other biotech financings
Ratio Therapeutics Raises $50M in Series B Financing
Leukemia Therapeutics Global Market Report 2023
TTI reviews parking model
TTI working round the clock to configure its systems

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

ABcann Global

CVE:ABC

B2Gold

NYSE:BTG
B2Gold Corp. operates as a gold producer company. It operates the Fekola Mine in Mali, the Masbate Mine in the Philippines, and the Otjikoto Mine in Namibia. The company also has an 100% interest in the Gramalote gold project in Colombia; 24% interest in the Calibre Mining Corp.; and approximately 19% interest in BeMetals Corp. In addition, it has a portfolio of other evaluation and exploration assets in Mali and Finland. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.
Cronos Group logo

Cronos Group

NASDAQ:CRON
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Genius Group logo

Genius Group

NYSEAMERICAN:GNS
Genius Group Limited, through its subsidiaries, provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company operates through two segments, Education and Campus. It develops comprehensive entrepreneurial education curriculum with a full suite of tools for student learning and faculty earning. The company also owns entrepreneur resorts in Bali and South Africa, which run entrepreneur retreats and workshops; and Genius Café, an entrepreneur beach club in Bali, as well as Genius Central, an entrepreneur co-working hub in Singapore. In addition, it offers home childcare and investment education services; operates entrepreneur education campus that provides a range of programs from pre-primary through primary school, secondary school, and vocational college; and provides career-focused on-campus and online programs at the master's, bachelor's and associate degree level, as well as certificate and continuing education programs. The company operates in Europe/the Middle East/Africa, the Asia/Pacific, and North America/South America. Genius Group Limited was founded in 2002 and is headquartered in Singapore.
Trillium Therapeutics logo

Trillium Therapeutics

NASDAQ:TRIL
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.